DrugBiological
Denileukin diftitox clinical trials
Also written ONTAK, E7777 and DAB389IL-2.
- studies test it
- 39
- open now
- 0
- in phase 3
- 2
- first study started
- 1995
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2005 (8)
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1999 | 2 |
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 8 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 27
- Phase 3
- 2
- Phase 4
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 25
Eisai Inc. (10) · University of Washington (3) · Eisai Co., Ltd. (2) · National Cancer Institute (NCI) (2) · Alexander B Olawaiye, MD (1) · Eastern Cooperative Oncology Group (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · The University of Texas Health Science Center at San Antonio (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (3) · Aldesleukin (2) · Pembrolizumab (1) · Etanercept (1) · Mycophenolic Acid (1) · Pentostatin (1) · Doxorubicin (1) · Vincristine (1)
Studies
Open first, then newest update. How each study uses denileukin diftitox is read from its arms, and is right about nine times in ten.
Testing it · 39
- T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsActive, not recruitingPhase 1/2Alexander B Olawaiye, MDNCT05200559Written as E7777
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT04855253Written as E7777
- A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaCompletedPhase 3Eisai Inc.NCT01871727Written as E7777 9 mcg/kg
- Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaCompletedPhase 2Eastern Cooperative Oncology GroupNCT00003615Written as denileukin diftitox
- Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV MelanomaTerminatedPhase 1/2Fred Hutchinson Cancer CenterNCT00945269Written as denileukin diftitox
- Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV MelanomaCompletedPhase 2Eisai Inc.NCT01127451Written as Denileukin diftitox
- Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)CompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT00224874Written as Denileukin Diftitox
- Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedPhase 2Eisai Co., Ltd.NCT02676778Written as E7777
- Vaccination Plus Ontak in Patients With Metastatic MelanomaTerminatedPhase 2University of ChicagoNCT00515528Written as Ontak
- Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)TerminatedPhase 2University of California, San FranciscoNCT00632827Written as Denileukin diftitox
- A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell LymphomaCompletedPhase 2Eisai Inc.NCT00211185Written as Denileukin diftitox
- Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell LeukemiaTerminatedPhase 2National Cancer Institute (NCI)NCT00117845Written as Denileukin diftitox (Ontak)
- Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube CancerCompletedPhase 1University of WashingtonNCT00357448Written as denileukin diftitox
- ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous TreatmentCompletedPhase 1/2University of WashingtonNCT00425672Written as ONTAK
- E7777 for the Treatment of Patients With Peripheral T-Cell LymphomaCompletedPhase 1Eisai Co., Ltd.NCT01401530Written as denileukin diftitox (E7777)
- A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian CancerCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT00880360Written as Ontak
- Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous TransplantationTerminatedPhase 1Barbara Ann Karmanos Cancer InstituteNCT01251952Written as Denileukin Diftitox (Ontak)
- Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00460109Written as denileukin diftitox
- Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedPhase 2Wake Forest University Health SciencesNCT00082940Written as denileukin diftitox
- Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin LymphomaWithdrawnNot applicableUniversity of MiamiNCT00513188Written as denileukin diftitox
See all 39 studies that test denileukin diftitox →
Given in every arm · 1 — denileukin diftitox is usual care beside what is tested
Codes
What other systems call denileukin diftitox · ClinicalTrials.gg INT003686
- MeSH (NLM) C078456denileukin diftitoxConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 25E79B5CTMDENILEUKIN DIFTITOXConfirmed FDA, NLM, Wikidata
- RxNorm 214470One source FDA
- Wikidata Q1187179denileukin diftitoxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1476Denileukin DiftitoxOne source FDA
- DrugBank DB00004One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C078456 | denileukin diftitox | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 25E79B5CTM | DENILEUKIN DIFTITOX | Confirmed FDA, NLM, Wikidata |
| RxNorm | 214470 | — | One source FDA |
| Wikidata | Q1187179 | denileukin diftitox | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1476 | Denileukin Diftitox | One source FDA |
| DrugBank | DB00004 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.